

CURRICULUM VITAE

Kevin MOORE

1. PERSONAL DETAILS

NAME	Kevin MOORE
PRESENT POSITION	Professor of Hepatology The UCL Institute of Liver and Digestive Health, Dept. of Medicine, Royal Free Campus University College London
EMAIL	kevin.moore@ucl.ac.uk
DATE OF BIRTH	19 th March 1958
NATIONALITY	British
MARITAL STATUS	Married

2. EDUCATION & QUALIFICATIONS

MEDICAL SCHOOL	King's College School of Medicine and Dentistry King's College London, 1977-1983
QUALIFICATIONS	BSc (Biochemistry, Intercalated), 1980 <i>First Class Honours</i> , King's College London University of London MB.BS. (University of London), 1983 MRCP, 1986 Ph.D (Biochemistry), University of London, 1993 <i>"Eicosanoids as determinants of renal function in liver disease"</i> FRCP , 1998

2. SPECIALIST REGISTER

- Gastroenterology
- Clinical Pharmacology and Therapeutics
- General Internal Medicine

3. PROFESSIONAL HISTORY

1999-2003	Senior Lecturer in Medicine, Centre for Hepatology Royal Free Campus, UCL
1994-1999	MRC Senior Clinical Fellow Centre of Hepatology, Dept. of Medicine, Royal Free Campus, UCL
1990-1994	Senior Registrar, Dept. of Clinical Pharmacology, Hammersmith Hospital, London
1988- 1990	MRC Training Fellow, The Liver Unit, King's College Hospital, London
1987-88	Clinical Research Fellow, The Liver Unit, King's College Hospital, London
1986-87	Medical Registrar, King's College Hospital, London
1985-86	Senior House Officer, Hammersmith Hospital
1984-85	Senior House Officer, St Bartholomew's Hospital Medical Rotation

4. OTHER APPOINTMENTS AND AFFILIATIONS

MEMBERSHIP OF PROFESSIONAL BODIES AND LEARNED SOCIETIES

Fellow of the Royal College of Physicians

Association of Physicians (secretary 2011-2013, Treasurer, 2013 til present)

Fellow of the Royal Society of Medicine

British Association for Study of the Liver

European Association for Study of the Liver

American Association for the Study of Liver Disease (AASLD)

Society for Free Radical Biology and Medicine (USA)

British Society of Gastroenterology

NATIONAL AND INTERNATIONAL COMMITTEES AND ADVISORY BODIES

INTERNATIONAL

Council Member Society for Free Radical Biology and Medicine (2005-2007)

Committee member of the International Ascites Club 1994-1997

Secretary for the International Ascites Club 1998-2001

Honorary Member of the Scientific Committee for the Italian Liver Foundation 1999 -

NATIONAL

Expert member of Gastroenterology, Rheumatology and infectious disease expert advisory group, Commission on Human Medicines, MHRA, 2010-present.

MHRA Committee on Paracetamol Overdose (developing new guidelines) 2011-2012.

Chair: Non alcoholic fatty liver disease group for the National Strategy for Liver Disease (2010 -2012)

Member of the Clinical Advisory Group (Nat. Strategy for Liver Disease (2010 -2012)

Chair: Writing of National Plan for Liver Services 2004 and 2010

Secretary: Working group Royal College of Physicians on Liver Services 2009

Liver Section Committee of the British Society of Gastroenterology 2008-2011

Expert member of gastroenterology committee, Commission on Human Medicines, MHRA, 2007 – 2009.

Research Committee of the British Society of Gastroenterology (BSG) 2002 -

Medical Advisory Committee of British Liver Trust (1997-2001)

Chairman of Working party on the commissioning of Liver Services BSG and BASL

Secretary of British Association for Study of the Liver (BASL) 1997-1999

British Association for Study of the Liver (BASL) Committee 1993-1997

PAST AND PRESENT LOCAL COMMITTEES

Regional

London New Drugs Group (2002- present), Department of Health Committee

Specialty Training Committee for Clinical Pharmacology (North London)

Specialty Training Committee for General Internal Medicine (North London)

Associate, Healthcare Commission

Local

Benchmarking Executive Committee (Royal Free Hospital)

Ethics Committee (Royal Free Hospital, 2001-2004)

Drug and Therapeutics Committee (1995-present)

Benchmarking committee for Food and Nutrition (Royal Free Hospital ~1998-2002)

EDITORIAL EXPERIENCE

I have been the associate editor for 3 journals, namely **GUT**, where I functioned as one of two associate editors that handle manuscripts on the liver, the **American Journal of Pathology**, where I handled manuscripts that involve oxidative stress, the liver and the kidney, and **Free Radical Biology and Medicine** which is a biochemical journal that is focused on free radicals in biology.

MEDICOLEGAL WORK

I have written ~200 medical reports on patients with either liver disease, or with issues relating to therapeutic or illicit drug use including inadvertent toxic exposure or overdose. I write simple and clear reports always quoting data and published evidence to support important statements or facts. I am a confident speaker.

Non-executive Director North Middlesex and University Hospital ~2008-2012

I served on the board as non-executive director for the Trust for 4 years, and chaired various committees. I enjoyed this role very much, although I found it very frustrating to see how slow the NHS is to implement new ideas and develop improvements independently of being forced to through local or national edicts.

APPLIED MEDICAL SCIENCES

I am the course director for the new Applied Medical Sciences Programme at UCL. I am also Education Lead for the Division of Medicine. This unique course uses eLearning for all of its lectures and we have opened a film studio, and delivered over 400 lectures using articulate storyline software. The course is unique in that it is a biomedical science course which fuses science with medicine, and yet encapsulates all that is needed to develop creativity and teamwork amongst our students. Thus there are four creative days per year held with an Arts tutor from St Martin's. Students also learn laboratory skills, and have access to a Laboratory Learning Hub. Students also learn inventive skills.

In 2017 we are also launching two new courses in Nutrition and Medical Sciences and Computational Medicine. The development of eLearning has been noted by UCL and we are now considered to be the lead course in this field. We are now developing eLearning for remote courses.

5. PUBLICATIONS

BOOKS

The Oxford Handbook of Acute Medicine. Ramrakha P. & Moore K.P. 1997

The Oxford Handbook of Acute Medicine. Ramrakha P. & Moore K.P. 2004

The Oxford Handbook of Acute Medicine. Ramrakha P., Moore K.P. & Sam A. 2010

This ~870 page handbook is part of a popular handbook series in Medicine. It covers all aspects of Acute Medicine. It has been highly successful.

The Oxford Desk Reference of Acute medicine. Leach, Moore and Bell. 2016

This book went to press in June 2016.

BOOK CHAPTERS

1. Hydrocortisone.
Therapeutic Drugs Ed. CT Dollery. Churchill Livingstone, Edin. 1991
2. Free Radicals in the vasculature: pathological & physiological significance.
Darley-Usmar V, Hogg N., Kalyanaraman, B., & **Moore K.P.**
In Oxidative Stress, Lipoproteins and Cardiovascular Function.
Ed. C. Rice-Evans and R. Bruckdorfer. Portland Press 1995 : 81-98.
3. Arachidonic acid metabolites and the kidney in cirrhosis. **Moore K. P.**
In Ascites & Renal dysfunction in Liver Disease V.Arroyo, P.Gines and J Rodes & R. Schrier: 1999.
4. The kidney in liver disease. **Moore K. P.**
In Comprehensive Clinical Hepatology. O'Grady, Lake and Howdale. 2000.
5. Ascites and portal Hypertension. **Moore K.P.**
Oxford Textbook of Medicine 4th Edition

PEER REVIEWED PUBLICATIONS

1. Frequency of acute pancreatitis in fulminant hepatic failure using isoenzyme markers. Ede R, **Moore K.P.**, Marshall WJ and Williams R. *Gut* 1988; **29**: 778-781.
2. Leukotriene C₄ elimination and metabolism in man. Maltby N, Taylor GW, Ritter J, **Moore K.P.**, Fuller R and Dollery CT. *Journal of Allergy and Clinical Immunology* 1990; **85**: 3-9.
3. Single total paracentesis for tense ascites: Sequential hemodynamic changes and right atrial size. Panos M, **Moore K.P.**, Vlavianos P, Chambers J, Anderson J, Gimson AES, Slater JDH, Rees LH, Westaby D and Williams R. *Hepatology* 1990; **11**: 662-667.
4. Increased production of cysteinyl-leukotrienes in hepatorenal syndrome. **Moore K.P.**, Taylor G, Maltby N, Siegers D, Fuller R, Dollery CT, and Williams R. *Journal of Hepatology* 1990; **11**: 263-271.
5. Renal and extra-renal production of prostacyclin and thromboxane in decompensated liver disease and hepatorenal syndrome. **Moore K.P.**, Ward P, Taylor G.W., and Williams R. *Gastroenterology* 1991; **100**: 1069-1077.
6. Metabolism of cysteinyl leukotrienes in man. Huber M, Muller J, Leier I, Jedlitschky G, Ball HA, **Moore K.P.**, Taylor G.W., Williams R, and D Keppler. *European Journal of Biochemistry* 1990; **194**: 309-315.
7. Cysteinyl-leukotriene production and oxidative metabolism by the isolated pig kidney. **Moore K.P.**, Wood J, Gove C, Tan KC, Eason J, Taylor GW and Williams R. *Kidney international* 1992; **41**: 1543-1548.
8. Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat. Wilkins MR, Settle SL, Kirk JA, Taylor SA, **Moore K.P.**, and RJ Unwin. *British Journal of Pharmacology* 1992; **107**: 50-57.
9. Plasma Immunoreactive endothelin in hepatorenal syndrome and liver disease. **Moore K.P.**, J Wendon, M Frazer, J Karani, R Williams, and K.F. Badr. *New England Journal of Medicine* 1992; **327**: 1774-1779.
10. Expression of the human neuropeptide tyrosine (NPY) Y₁ receptor. J Wharton, L Gordon, J Byrne, H Herzog, L Selbie, **Moore K.P.**, M Sullivan, M Elder, G Moscoso, K Taylor, J Shine, and J Polak. *Proceedings of the National Academy of Sciences* 1993; **90**: 687-691.
11. Marked overproduction of non-cyclooxygenase derived F₂-isoprostanes in the hepatorenal syndrome. Morrow JD., **Moore K.P.**, Awad J., Badr KF., Williams R. Roberts LJ. *Journal of Lipid Mediators*; 1993: **6**:417-20.
12. Induction of nitric oxide synthase in cultured vascular smooth muscle cells: the role of cyclic AMP. Hirokawa K, O'Shaughnessy K, **Moore K. P.**, Ramrakha P, & Wilkins M. *British Journal of Pharmacology* 1994; **112**: 396-402.
13. Formation of F₂-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. **Moore K.P.**, Darley-Usmar V. Morrow J. Roberts LJ. *Circulation Research* 1995; **77**: 335-341.
14. Mesenteric vasodilator responses in cirrhotic rats: a role for nitric oxide? Mathie R.T, Ralevic V, **Moore K.P.**, and Burnstock G. *Hepatology* 1996; **23**: 130-136.)
15. Vasoconstrictor responsiveness of the rat mesenteric arterial bed in cirrhosis. Ralevic V, Mathie R.T, **Moore K.P.**, and G. Burnstock. *British Journal of Pharmacology* 1996; **118**: 435-441.

18. Identification of the major urinary metabolite of the F₂-isoprostane 8-isoprostaglandin F_{2α} in humans. Roberts L.J, **Moore K.P.**, Zackert W, and Morrow J. D. ***Journal of Biological Chemistry* 1996: 271; 34: 20617-20620**
19. 8-Isoprostaglandin F_{2α} a product of lipid peroxidation increases portal pressure in normal and cirrhotic rats. Marley R, Harry D, Fernando B, Anand R, and **Moore K.P.** ***Gastroenterology* 1997; 112: 208-213**
20. N-Acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. B. Fernando, R. Marley, S. Holt, R. Anand, D. Harry, P. Sanderson, R. Smith, G. Hamilton, and **K. P. Moore.** ***Hepatology* 1998: 28: 689-94.**
21. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis induced renal failure. Moore K.P, Holt S.G., Patel R.P Svistunenko D.A, Zackert W., Goodier D., Reeder B., Clozel M, Anand R., Cooper C.E., Morrow J.D., Wilson M., Darley-USmar V., and L.J. Roberts II. ***Journal of Biological Chemistry* 1998: 273: 31731-31737.**
23. Acute cholestasis-induced renal failure: Effects of anti-oxidants and ligands for the thromboxane A₂ receptor. Holt S., Marley R., Fernando B., Harry D, Anand R, Goodier D, and **Moore K.P.** ***Kidney International* 1999: 55: 271-277.**
24. N-Acetylcysteine improves renal function in the hepatorenal syndrome. S. Holt, D. Goodier., Marley R., Patch D., Burroughs A., Fernando B., Harry D & **Moore K.P.**, ***Lancet* 1999: 353: 294-295.**
25. Increased lipid peroxidation in Rhabdomyolysis. S.G Holt, Goodier D, Reeder B, Harvey S., Morrow J.D., Wilson M.T., Roberts L.J and **Moore K.P.** ***Lancet* 1999: 353: 1471.**
26. Quantitation of the major urinary metabolite of the 15-F_{2t}-isoprostane (8-iso-PGF₂) by a stable isotope dilution mass spectrometric assay. Morrow JD. Zackert WE. Yang JP. Kurhts EH. Callewaert D. Dworski R. Kanai K. Taber D. **Moore K.P.**, Oates JA. Roberts LJ. ***Analytical Biochemistry* 1999: 269:326-331.**
27. Lipoic acid prevents development of the hyperdynamic circulation in rats with biliary cirrhosis. Marley R., Holt S.G., Fernando B., Goodier D., Harry D., and Moore K.P. ***Hepatology* 1999:29:1358-63.**
28. Increased sensitivity to endotoxemia in the bile-duct ligated cirrhotic rat. Harry D., Anand R., Holt S., Marley R., Goodier D., and Moore K.P. ***Hepatology* 1999: 30:1198-1205.**
30. A chemiluminescence based assay for S-nitrosoalbumin and other plasma S-nitrosothiols. R. Marley, M. Feelisch, S. Holt and Moore K.P. ***Free Radical Research* 2000: 32: 1-9.**
31. Analysis of free and protein bound nitrotyrosine in human plasma by a gas chromatography method that avoids artefactual nitration. Frost. M., Halliwell. B., and Moore K.P. ***Biochemical Journal* 2000:345: 453-8**
32. Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Turvill JL, Burroughs AK, & **Moore K.P.** ***Lancet* 2000:355: 2048-9.**
33. Formation of nanomolar concentrations of S-nitroso-albumin in human plasma by nitric oxide. Marley R, Patel R.P., Orie N., Ceaser E., Darley-USmar V and **Moore. K.P.** ***Free Radical Biology and Medicine* 2001: 31: 688-696.**
34. Increased formation of S-nitrosothiols and nitrotyrosine in cirrhotic rats during endotoxemia. L.H. Ottesen, D. Harry, M. Frost., Susan Davies, K. Khan, B. Halliwell and **Moore. K.P.** ***Free Radical Biology and Medicine* 2001: 31: 790-798.**

35. Endothelial Transcytosis of Myeloperoxidase Confers Specificity to Vascular Extracellular Matrix Proteins as Targets of Tyrosine Nitration. Baldus S., Eiserich J.P., Mani A., Castro L., Figueroa M., Chumley P., Ma W., Tousson A. White R., **Moore K.P.**, & Freeman B.A. ***Journal of Clinical Investigation* 2001;108:1759-1770.**
36. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. R. Anand, D. Harry, S. Holt, P. Milner, M. Dashwood, D Goodier, M. Jarmulowicz, and **K.P. Moore.** ***Gut* 2002; 50: 111-117.**
37. Repetitive myocardial stunning in pigs is associated with an increased formation of reactive nitrogen species. Baker, C.S., Frost, M.T., Rimoldi, O., **Moore, K.P.**, Halliwell, B., Polak, J.M., Camici, P.G., Hall, R.J. ***Heart* 2002 ;87(1):77-8..**
38. The metabolic fate of dietary polyphenols in humans. Rechner A. Kuhnle G, Bremner P., Hubbard G., **Moore K.P.**, & C. Rice-Evans. ***Free Radical Biology and Medicine* 2002; 33 (2) 220-235.**
39. The ingestion of inorganic nitrate increases gastric S-nitrosothiol levels and inhibits platelet function in humans. Richardson G., Hicks S.L., Frost M.T., **Moore K.P.**, Benjamin N., and G.M. McKnight. ***Nitric Oxide* 2002; 7: 24-29.**
40. The metabolism of dietary polyphenols and the relevance to circulating levels of conjugated metabolites. AR Rechner, G Kuhnle, H Hu, A Roedig-Penman, M van den Braak, **Moore K.P.**, Rice-Evans C. ***Free Radical Research* 2002 ;36:1229-41.**
41. Crane MS1, Ollosson R, Moore KP, Rossi AG, Megson IL. Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function. ***J Biol Chem.* 2002;277(49):46858-63.**
42. Discovery of new products of lipid peroxidation formed *in vivo* with a substituted tetrahydrofuran ring (isofurans) that are up-regulated by increased oxygen tension. Fessel J.P, Porter N.A, **Moore K.P.**, Sheller J.R., and L.J. Roberts. ***Proceedings of the National Academy of Sciences (USA)* 2002;99:16713-8.**
43. The effect of dietary nitrate on salivary, plasma and urinary nitrate metabolism in humans. A.S. Pannala, A.R. Mani, J. P. E. Spencer, V. Skinner, K. R. Bruckdorfer, **K. P. Moore** and C.A. Rice-Evans. ***Free Radical Biology and Medicine* 2003; 1;34:576-84.**
44. Peroxynitrite induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. B. Ferraro, F. Galli, B. Frei, E. Kingdon, F. Canestrari, C.A Rice-Evans, U. Buoncristiani, A. Davenport & **K. P. Moore.** ***Kidney International* 2003 ;63:2207-13.**
45. Mani AR, Pannala AS, Orie NN, Ollosson R, Harry D, Rice-Evans CA, Moore KP. Nitration of endogenous para-hydroxyphenylacetic acid and the metabolism of nitrotyrosine. ***Biochemical Journal.* 2003;374:521-7.**
46. Rechner AR, Smith MA, Kuhnle G, Gibson GR, Debnam ES, Srai SK, Moore KP, Rice-Evans CA. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. ***Free Radical Biology and Medicine.* 2004;36:212-25.**
47. Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Mani AR, Moore K, Miller GJ, Humphries SE, Hurel SJ, Montgomery HE Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. ***European Heart Journal.* 2004;25:468-75**
48. Martin HM, Moore KP, Bosmans E, Davies S, Burroughs AK, Dhillon AP, Tosh D, Harrison R Xanthine oxidoreductase is present in bile ducts of normal and cirrhotic liver. ***Free Radical Biology and Medicine.* 2004;37:1214-23**

49. Orie N, Vallance P, Jones D, **Moore KP**. S-nitroso-albumin carries a thiol-labile pool of nitric oxide which causes venodilation in the rat. *American Journal of Physiology*. 2005;289:H916-23.
50. Ebrahimkhani MR, Mani AR, **Moore K.P** Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis. *Gut*. 2005 54:1668-7.
51. Mani, AR., Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with cirrhosis. *Hepatology*. 2006;43:847-56.
52. Mani AR, Ollosson R, Mani Y, Ippolito S, **Moore KP**. Heart rate dynamics in iNOS knockout mice. *Life Sciences*. 2006 79:1593-9.
53. Mani AR, Ebrahimkhani MR, Ippolito S, Ollosson R, **Moore KP**. Metalloprotein-dependent decomposition of S-nitrosothiols: studies on the stabilization and measurement of S-nitrosothiols in tissues. *Free Radical Biology and Medicine*. 2006; 40:1654-63.
54. Ebrahimkhani M, Kiani S, Oakley F, Kendall T, Sharifabrizi A, Tavangar SM, Moezi L, Payabvash S, Karoon A, Hoseininik H, Mann DA, **Moore KP**, Mani AR, Dehpour AR. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. *Gut*. 2006; 55: 1606-16;
55. Pannala AS, Mani AR, Rice-Evans CA, **Moore KP**. pH-dependent nitration of para-hydroxyphenylacetic acid in the stomach. *Free Radical Biology and Medicine*. 2006; 41:896-901.
56. Mani AR, Ippolito S, Moreno JC, Visser TJ, **Moore KP**. The metabolism and dechlorination of chlorotyrosine in vivo. *Journal of Biological Chemistry*; 2007;282:29114-21
57. Kuhnle GG, Story GW, Reda T, Mani AR, **Moore KP**, Lunn JC, Bingham SA. Diet-induced endogenous formation of nitroso compounds in the GI tract. *Free Radical Biology and Medicine*. 2007;43; 1040-7.
58. Wright G, Davies NA, Shawcross D, Hodges SJ, Zwingmann C, Brooks HF, Mani AR, Harry D, Stadlbauer V, Zou Z, Williams R, Davies C, **Moore KP**, Jalan R. Endotoxemia produces coma and brain swelling in bile duct ligated rats. *Hepatology*. 2007;45:1517-26.
59. Ghasemi M, Sadeghipour H, Shafaroodi H, Nezami BG, Gholipour T, Hajrasouliha AR, Tavakoli S, Nobakht M, **Moore KP**, Mani AR, Dehpour AR. Role of the nitric oxide pathway and the endocannabinoid system in neurogenic relaxation of corpus cavernosum from biliary cirrhotic rats. *British Journal of Pharmacology*. 2007;151:591-601.
60. Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. *Hepatology*. 2008;47(1):160-8.
61. Stadlbauer V, Wright GA, Banaji M, Mukhopadhyaya A, Mookerjee RP, **Moore K**, Jalan R. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. *Gastroenterology*. 2008;134:111-9.
62. Hoehn T, Janssen S, Mani AR, Brauers G, **Moore KP**, Schadeewaldt P, Mayatepek E. Urinary excretion of the nitrotyrosine metabolite 3-nitro-4-hydroxyphenylacetic acid in preterm and term infants. *Neonatology*. 2008;93:73-6.
63. Mani AR, Montagnese S, Jackson CD, Jenkins CW, Head IM, Stephens RC, **Moore KP**, Morgan MY. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. *Am J Physiol Gastrointest Liver Physiol*. 2009;296:G330-8.
64. Kumar S, Hall RJ, Mani AR, **Moore KP**, Camici PG, Rimoldi OE, Williams AJ, Macleod KT.

- Myocardial stunning is associated with impaired calcium uptake by sarcoplasmic reticulum. **Biochemical Biophysical Research Communications**. 2009; 387:77-82.
65. M. N. Hughes, Centelles M., **Moore K.P** Making and working with hydrogen sulfide: The chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: **Free Radical Biology and Medicine** 2009: 47;10;1346–1353
 66. Charunwatthana P, Abul Faiz M, Ruangveerayut R, Maude RJ, Rahman MR, Roberts LJ 2nd, Moore K, Bin Yunus E, Hoque MG, Hasan MU, Lee SJ, Pukrittayakamee S, Newton PN, White NJ, Day NP, Dondorp AM. N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. **Crit Care Med**. 2009;**37(2):516-22**
 67. Boudaud O, **Moore KP**, Reeder BJ, Harry D, Howie AJ, Wang S, Carney CK, Masterson TS, Amin T, Wright DW, Wilson MT, Oates JA, Roberts LJ Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. **Proceedings of the National Academy of Sciences** 2010; **107:2699-704**.
 67. Ghasemi M, Rezaia F, Lewin J, **Moore KP**, Mani AR.D-Serine modulates neurogenic relaxation in rat corpus cavernosum. **Biochemical Pharmacology**. 2010; **79:1791-6**.
 68. Ghasemi M, Dehpour AR, Moore KP, Mani AR. Role of endogenous hydrogen sulfide in neurogenic relaxation of rat corpus cavernosum. **Biochemical Pharmacology** 2012.
 69. Gholami M, Mazaheri P, Mohamadi A, Dehpour T, Safari F, Hajizadeh S, Moore KP, Mani AR. Endotoxemia is Associated With Partial Uncoupling of Cardiac Pacemaker From Cholinergic Neural Control in Rats. **Shock**. 2012 ;**37(2):219-27**.
 70. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, Mann GE, Moore K, Roberts LJ 2nd, Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. **Free Radic Biol Med**. 2012;**52(1):1-6**.
 71. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, Paradis V, Moore K, Mookerjee R, Jalan R. **Liver Int**. 2013;**33:398-409**
 72. Slack A, Tredger M, Brown N, Corcoran B, Moore K. Application of an isocratic methanol-based HPLC method for the determination of iohexol concentrations and glomerular filtration rate in patients with cirrhosis. **Ann Clin Biochem**. 2014;**51(Pt 1):80-88**
 73. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. **Gut**. 2015;**64(4):531-7**.
 74. Mazza G, Rombouts K, Rennie Hall A, Urbani L, Vinh Luong T, Al-Akkad W, Longato L, Brown D, Maghsoudlou P, Dhillon AP, Fuller B, Davidson B, Moore K, Dhar D, De Coppi P, Malago M, Pinzani M. Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. **Sci Rep**. 2015 Aug 7;**5:13079**. doi: 10.1038/srep13079
 75. Hamilton F, Hornby J, Sheringham J, Kerry S, Linke S, Solmi F, Ashton C, Moore K.P, Murray E. Digital Alcohol Management ON Demand (DIAMOND) feasibility randomised controlled trial of a web-based intervention to reduce alcohol consumption in people with hazardous and harmful use versus a face-to-face intervention: protocol. **Pilot and Feasibility Studies** 2015.
 76. Mani AR, Moreno JC, Visser TJ, Moore KP. The metabolism and de-bromination of bromotyrosine in vivo. **Free Radic Biol Med**. 2016 Jan;**90:243-51**

77. Perlemuter G, Cacoub P, Valla D, Guyader D, Saba B, Batailler C, Moore K. Characterisation of agomelatine induced liver enzymes: Incidence and risk factors. A pooled analysis of 7605 treated patients: **CNS Drugs. 2016 Sep;30(9):877-88.**
78. Bell S, Mehta G, Moore K, Britton A. Ten-year alcohol consumption typologies and trajectories of C-reactive protein, interleukin-6 and interleukin-1 receptor antagonist over the following 12 years: a prospective cohort study. **J Intern Med. 2016 Aug 3. doi: 10.1111/joim.12544.**

REVIEWS & REQUESTED ARTICLES

1. Management of severe paracetamol poisoning.
Drug and Therapeutics Bulletin. 1988;26(25):97-99. Original draft.
2. Management of renal failure associated with acute liver failure.
Moore KP and Williams R. Care of the Critically Ill. 1989;5:61-64.
3. Pathogenesis of ascites and hepatorenal syndrome.
Wilkinson SP, **Moore K.P.**, and Arroyo V. **Gut 1991 (suppl) S12-S17.**
4. Conference Report. Impact of the new biology on research and teaching.
Dollery C.T& **Moore K.P. Lancet 1992; 339 p607**
5. The Hepatorenal Syndrome. Van Roey G., and **Moore K.P.**
Pediatric Nephrology 1996; 10:100-107
6. Hepatorenal Syndrome. **Moore K.P**
Clinical Science; 1997: 92: 433-443
7. Bile acids, oxidative stress and renal function in obstructive jaundice. Bomzon A, Holt S, & **K.P. Moore. Seminars in nephrology 1997;17: 549-562.**
8. Measurement of lipid peroxidation. **Moore K.P.** & L.J Roberts.
Free Radical Research 1998: 28: 659-671
9. Cytochrome p450 metabolites and renal function in cirrhosis: The HETE is on.
Moore K.P. Hepatology 1998: 27: 1166-1168.
10. Renal failure in acute liver failure. **Moore K.P.**
European Journal of Gastroenterology 1999: 11: 967-985.
11. Pathogenesis of Renal Failure in Rhabdomyolysis: Role of Myoglobin.
S. Holt and **Moore K.P. Experimental Nephrology 2000; 8: 72-76**
12. Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Dagher L, Patch D, Marley R, Moore K.P., & Burroughs A. **Alimentary Pharmacology & Therapeutics 2000;14:515-21**
13. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis.
Holt S.G & **Moore K.P. Intensive Care Medicine 2001: 27: 803-811**
14. Nitric Oxide and the Liver. Farzaneh-Far R., and **Moore K.P.**
Liver 2001: 21 (3): 161-74

15. Management of alcoholic hepatitis. **Moore K.P.**
Clinical Medicine 2001; 1 : 281-284.
16. The Hepatorenal Syndrome. Dagher L & **Moore K.P.**
Gut 2001 49: 729-737.
17. Different effects of tacrolimus and cyclosporine on renal haemodynamics and blood pressure in healthy subjects. Analysis and commentary. Holt S.G and **Moore K.P.**
Transplantation 2002; 73 : 673-674.
18. Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and subarachnoid haemorrhage. Reeder BJ, Sharpe MA, Kay AD, Kerr M, Moore K, Wilson MT.
Biochem Soc Trans 2002;30:745-8 .
19. Measurement of protein nitration and S-nitrosothiol formation in biology and medicine **Moore K.P.** & Mani A.R. ***Methods in Enzymology 2002 359:256-68.***
20. The Management of Ascites in Cirrhosis – Report on the Consensus Conference of the International Ascites Club. **Moore K.P.**, Wong F., Gines P., Bernardi M., Ochs A., Salerno F., Jimenez W., Angeli P., Porayko M., Moreau R., Garcia-Tsao G., Planas R., and V. Arroyo.
Hepatology 2003; 38:258-66.
21. Thursz M, Moore K. Clinical management. Where medicine meets management. Can of worms.
Health Serv J. 2004 Mar 4;114(5895):28-9.
22. Mani AR and Moore K.P. Dynamic assessment of nitration reactions *in vivo*. ***Methods in Enzymology 2005; 396, pt E. 151-160.***
23. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis.
Gut. 2006 ; 55 Suppl 6:vi1-vi12.
24. Mani AR, Moore KP.
New insights into the role of endogenous opioids in the pathogenesis of gastrointestinal and liver disease. ***Gut. 2009;58:893-5***
25. Moore K, Sheron N. Why we need a national strategy for liver disease. ***Br J Hosp Med (Lond). 2009;70(12):674-5.***
26. Gines P, Angeli P, Lenz K, Moller, S, **Moore K.P.**, Moreau R and C. Merkel. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. ***J Hepatol. 2010;53(3):397-417.***

Short articles and case reports

Late diagnosis of pituitary and parapituitary lesions causing visual failure.

Moore K.P, Wass JAH, and Besser GM. ***British Medical Journal 1986; 293:609-610***